Resistance in the anti-angiogenic era: nay-saying or a word of caution?
Related Experiment Video
Updated: Sep 27, 2026
Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays
Published on: September 19, 2018
Christopher J Sweeney1, Kathy D Miller, George W Sledge
1Indiana University, 535 Barnhill Drive, Room 473, Indianapolis, IN 46202, USA. chsweene@iupui.edu
Abstract:
The hope that anti-angiogenic therapy might be the panacea for cancer has not yet been realized. There are many possible reasons for this, including endothelial and tumor cell heterogeneity, the presence of survival factors within the tumor micro-environment, the problem of defining the best dose and schedule for anti-angiogenic therapies, and angiogenesis-independent regrowth of tumors. Once these problems are understood, we can begin to evaluate approaches to thwarting them. These could include combining anti-angiogenic therapies with chemotherapy, with other anti-angiogenic agents or with other biological therapies. Another approach would be to employ a particular agent or combination of agents that target processes crucial to the survival of a particular cancer.
Insights
Anti-angiogenic therapy shows promise but faces challenges like tumor heterogeneity and survival factors. Combining therapies or targeting specific cancer survival processes may improve effectiveness.
Area of Science:
- Oncology
- Cancer Biology
- Pharmacology
Background:
- Anti-angiogenic therapy, aimed at inhibiting tumor blood vessel formation, has not yet achieved its full potential as a cancer treatment.
- Several factors contribute to its limited success, including tumor and endothelial cell variability, protective tumor microenvironments, and difficulties in optimizing drug dosage and scheduling.
Purpose of the Study:
- To explore the reasons behind the limited efficacy of anti-angiogenic therapy in cancer treatment.
- To identify potential strategies to overcome these limitations and enhance therapeutic outcomes.
Main Methods:
- The study reviews existing research and clinical observations regarding anti-angiogenic therapy challenges.
- It discusses potential combination strategies and targeted approaches for improving cancer treatment efficacy.
Main Results:
- Tumor cell and endothelial cell heterogeneity present significant hurdles.
- Tumor micro-environment survival factors and angiogenesis-independent tumor regrowth impede treatment success.
- Optimizing anti-angiogenic therapy dosage and scheduling remains a challenge.
Conclusions:
- Overcoming the limitations of anti-angiogenic therapy requires a deeper understanding of tumor biology.
- Combining anti-angiogenic agents with chemotherapy, other anti-angiogenic drugs, or biological therapies shows promise.
- Developing targeted agents that disrupt critical cancer survival pathways is a key future direction.
More Related Videos
08:09Validation of Nanobody and Antibody Based In Vivo Tumor Xenograft NIRF-imaging Experiments in Mice Using Ex Vivo Flow Cytometry and Microscopy
Published on: April 6, 2015
11:02Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction
Published on: September 14, 2018
